secwatch.observer — SEC 8-K summary
======================================

Issuer:     Innoviva, Inc. (INVA)
CIK:        0001080014
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001104659-25-045556
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Innoviva Q1 net loss $46.6M on $78.8M investment write-down; IST sales up 52%
-----------------------------------------------------------------------------

- Net loss of $46.6M ($0.74/share) vs net income of $36.5M in Q1 2024 due to $78.8M unfavorable fair value changes on equity investments.
- Royalty revenue from GSK was $61.3M, largely flat year-over-year.
- U.S. net product sales from IST (GIAPREZA, XACDURO, XERAVA) grew 52% to $26.4M; total net product sales $30.3M.
- Income from operations rose 61% to $41.4M; cash and equivalents $319.1M at quarter end.
- Zoliflodacin NDA on track for H1 2025 filing; ZEVTERA U.S. launch expected mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1080014/000110465925045556/0001104659-25-045556-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1080014/000110465925045556/tm2514212d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-045556

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer